Nausea and vomiting induced by chemotherapy is a variable response related to the nature and intensity of treatment and patient susceptility. The mechanism whereby chemotherapy evokes nausea and vomiting is uncertain but recently, the ability of 5-HT3 receptor antagonists to antagonise chemotherapy induced emesis in animals (Costall et al., 1986; Miner & Sanger, 1986) and man (Cunningham et al., 1987; Leibundgut & Lancranjan, 1987; Kris et al., 1989) 
Nausea and vomiting induced by chemotherapy is a variable response related to the nature and intensity of treatment and patient susceptility. The mechanism whereby chemotherapy evokes nausea and vomiting is uncertain but recently, the ability of 5-HT3 receptor antagonists to antagonise chemotherapy induced emesis in animals (Costall et al., 1986; Miner & Sanger, 1986) and man (Cunningham et al., 1987; Leibundgut & Lancranjan, 1987; Kris et al., 1989) has focused interest on the role of 5-hydroxytryptamine (5-HT). It has been hypothesised that emetogenic chemotherapeutic agents may release 5-HT to trigger the emetic reflex via 5-HT3 receptors located at central sites or on the afferent vagus nerve Hawthorne et al., 1988; Higgins et al., 1989) . 5-HT is found in high concentration in the enterochromaffin cells and platelets and a release of 5-HT from such sites would be expected to elevate the circulating levels of 5-HT (Verbeuren, 1989 by HPLC with electrochemical detection. The HPLC systems consisted of a Spectra-Physics IsoChrom liquid chromatography pump, Wisp 710B automatic injection (Waters) and hypersil-ODS (250 x 4.6 mm, 5 jlm particle size, HPLC Technology) analytical columns. The electrochemical detector was a ESA Coulochem (5100A) with 5011 analytical cell (detector 1, + 0.05 V; detector 2, + 0.40 V). Peaks due to oxidation, at detector 2, in the column elevates were recorded on a Hewlett-Packard 3392A printing integrator. The HPLC-ECD system, except the integrator was maintained at 4°C. The mobile phase for the separation of indoleamines consisted of a mixture of 0.2 mol dm-3 disodium hydrogen ortho-phosphate (AnalaR Grade, BDA) and 0.1 mol dm 3 Citric acid (AnalaR Grade BDH), pH 6.3, with 11% vol/vol methanol (Analytical Reagent Grade, May & Baker) and 2.0 mol dm-3 tetraethylammonium bromide (Pariss Grade, Fluka) pumped at a rate of 1.3 ml min -l.
Vomiting was assessed as an all or none event by the night sister and respective nurses on the ward. A record was also made of the time of each emetic episode and if additional antiemetic treatment was given.
Plasma levels of 5-HT are normally of the order of 0.1-5 ng ml-' and their detection necessitates a highly sensitive HPLC-ECD technique; the limits of sensitivity (SNR= 3) of the present technique was approximately 100 pg ml'. Since the plasma levels of 5-HT are very low compared to the concentration of 5-HT in the platelets, care was taken in the sampling procedure to avoid plasma 5-HT contamination by disruption of platelets. This was achieved by discarding the first 5ml of withdrawn blood and using the subsequent 2.7 ml sample.
The 5-HT concentration in the plasma before cisplatin treatment was 386 ± 104 pg ml' for the ten patients (mean ± s.e.m.). Measurements taken at 2 h after cisplatin infusion revealed no changes in the plasma levels of 5-HT but subsequently there were marked inter-patient differences. Thus 4 h readings in patients I and II indicated dramatic 700-800% increases in plasma 5-HT levels which had returned to control levels after 6-8 h. In a further two patients III and IV the control levels were maintained for 6 h before 500-1,000% increases in plasma 5-HT levels were recorded at 8 h; measurements taken at 16 h indicated a return to baseline values. In the remaining six patients (V to X) the levels of plasma 5-HT did not change significantly over the 24 h period of assessment (Figure 1) . Ethical considerations required the use of concomitant Measurement of plasma levels of 5-HT taken before cisplatin infusion were comparable to literature values for control subjects (Ortiz et al., 1988) . Values were unchanged during the 2 h period following cisplatin treatment but the subsequent marked increase in plasma 5-HT levels in four patients attained 5-hydroxyindole levels previously found in the carcinoid syndrome (Feldman et al., 1974; Tyce & Creagan, 1981) . There were temporal differences in the appearance of the peaks of 5-HT in the plasma; in two patients the response attained maximum within 4 h while peaks occurred at 8 h in the other two patients. In the remaining six patients, at least at the selected times of measurement, there was no change in plasma 5-HT levels. However, since the peaks of 5-HT when occurring could return to baseline values within 2 h, it is possible that the measurements spaced at 8, 16 and 24h may have failed to detect changes during these time periods. The study indicates that a 2 h sampling would be preferred in subsequent studies to obtain a more detailed profile of biochemical change.
The design of the study to allow patients an appropriate In addition to the attempts to control emesis, patients were hydrated to reduce the possibility of toxicity. Therefore it is possible that the hydration/anti-emetic therapy may actually have contributed to the increased plasma 5-HT levels. But there is no evidence that lorazepam, metoclopramide or dexamethasone or hydration techniques can elevate plasma 5-HT levels and in any event, in the present study, six patients treated with such regimens failed to show any change in plasma 5-HT levels.
In those patients with an elevated circulating 5-HT level the 5-HT may influence central and or peripheral 5-HT3 receptors to induce emesis . Such patients may be those in whom the 5-HT3 receptor antagonists such as granisetron and ondansetron cause a complete or major inhibition of emesis (Carmichael et al., 1989; Marty et al., 1990) . However, in the latter studies the 5-HT3 receptor antagonists were highly effective in at least 75% of patients, which does not correlate with the 40% of patients only in the present study showing a raised plasma 5-HT level. Furthermore, Cubeddu et al. (1990) have reported that all patients treated with cisplatin (at a dose at least twice that of the present study) had a significant increase in urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA) which paralleled the onset and development of emesis. The increases in 5-HIAA were suggested to reflect the release of 5-HT from enterochromaffin cells. Our findings are supportive of the hypothesis that an increase in urinary 5-HIAA levels may reflect increased levels of plasma 5-HT. In the present study the lesser incidence of patients showing changes in 5-HT levels may reflect the small patient sample and lesser dosage regimen of cisplatin.
A corollary of the above discussion is that the 5-HT3 receptor antagonists would be expected to have little action in the absence of a raised 5-HT function. In these cases, a component of emesis could be envisaged to be induced via other unspecified neurotransmitter system(s) and account for the small proportion of patients that do not respond to the 5-HT3 receptor antagonists with complete control. The results of the present study and that of Cubeddu et al. (1990) indicate the importance of developing these investigations further using both plasma and urine measurements of 5-HT and or 5-HIAA, to more fully establish the role of 5-HT in chemotherapy induced emesis.
